UK PR pitch could portend US acquisitions for AstraZeneca

Share this article:
AstraZeneca is reviewing its UK financial PR business amid media speculation on a possible acquisitions run in the US, reports our sister publication, PRWeek UK.

The company is hearing pitches from multiple City of London communications agencies including incumbent Brunswick, FD, Finsbury and Tulchan Communications, all of which specialize in financial PR.

The business is worth a sum in the low six figures in fees, though project work around mergers and acquisitions could pad that out considerably, reported PRWeek UK. The review comes amid speculation that the company could buy Shire and beef up its US operations through acquisitions. 
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...